British pharmaceutical giant GSK agrees to acquire Canadian Bellus Health

British pharmaceutical company GSK (GlaxoSmithKline) announced that it has reached an agreement to acquire Canadian pharmaceutical company Bellus Health for 1.6 billion pounds (2 billion dollars). In a statement made by GSK, it was noted that an agreement was reached to acquire Bellus Health for 1.6 billion pounds (2 billion dollars) for 14.75 dollars per share. The statement stated that the Canadian pharmaceutical company specializes in respiratory problems and cough treatment in particular, and that the acquisition agreement is expected to make a significant contribution to GSK in these areas. The statement emphasized that the drug called “Camlipixant” developed by Bellus Health and found to be good for coughs is currently in the final stages of clinical testing, and it was also reminded that 6 million people in the US and the European Union suffer from chronic cough.